Lupin Introduces Ramipril Capsules

Lupin Pharmaceuticals has announced that the FDA has granted final approval for its abbreviated new drug application for Ramipril capsules, 1.25mg. 2.5mg, 5mg and 10mg. Commercial shipments of the product have commenced.

Lupin’s Ramipril capsules are the AB-rated generic equivalent of King Pharmaceutical’s Altace capsules, indicated for the treatment of hypertension.

On June 5, 2008, in an effort to restrict Lupin’s launch, King filed a motion for a temporary restraining order and preliminary injunction against Lupin Pharmaceuticals. The hearing occurred June 10, 2008 and King’s motion was denied.

Bob Hoffman, vice president of sales and marketing at Lupin, said: “This has been a hard fought battle and reflects Lupin’s determination to continue its efforts to bringing quality, affordable generic alternatives to our customers.”